[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600537":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":44,"responsibleParty":72,"collaborators":17,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":17,"eligibilityCriteria":80,"healthyVolunteers":77,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":17,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":46,"whyStopped":17,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Patel Hospital, Pakistan","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Transamine","EXPERIMENTAL","At the time of incision, 1000mg of the drug would be given intravenous, followed by two postoperative doses of 1000mg eight hours apart.",[13],"Drug: Tranexamic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",null,[19],"Other: Normal Saline (Placebo)",[21,25],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":17},"DRUG","Tranexamic Acid",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":17},"Normal Saline (Placebo)","At the time of incision, 10ml of the drug would be given intravenous, followed by two postoperative doses of 10ml eight hours apart.",[15],[30],{"name":31,"affiliation":32,"role":33},"Ghulam Murtaza, MBBS, FCPS, MRCS, MSc (epi)","Patel Hospital","STUDY_DIRECTOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":17,"email":39},"Yusra Jamshed, MBBS","CONTACT","+923343914332","yusra.j.khan@gmail.com",{"name":41,"role":37,"phone":42,"phoneExt":17,"email":43},"Umama Ehtisham, MBBS","+923323551441","umamas15@gmail.com",[45],{"facility":32,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Karachi","Sindh","75300","Pakistan","PK",{"type":53,"coordinates":54},"Point",[55,56],67.0104,24.8608,{"lat":56,"lon":55},[59,63,66,68,70],{"name":60,"role":37,"phone":61,"phoneExt":17,"email":62},"Shabana Tabbasum, MSc, PG Dip(Bioethics)","021 111 174 174","erc@patel-hospital.com",{"name":31,"role":37,"phone":64,"phoneExt":17,"email":65},"+923332064163","gms786@gmail.com",{"name":36,"role":67,"phone":17,"phoneExt":17,"email":17},"PRINCIPAL_INVESTIGATOR",{"name":41,"role":69,"phone":17,"phoneExt":17,"email":17},"SUB_INVESTIGATOR",{"name":71,"role":69,"phone":17,"phoneExt":17,"email":17},"Fariha Faizan, MBBS, FCPS",{"type":67,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Yusra Jamshed","Principal Investigator- Trainee General Surgery","100600537","phase-4-role-of-tranexamic-acid-in-reducing-hemorrhagic-events-in-bariatric-surgery-100600537",false,"NCT07098780","Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery","Inclusion Criteria:\n\n* Patients above 18 years of age AND\n* Undergoing Laparoscopic Sleeve Gastrectomy and MGB\n* Morbid obesity\n\nExclusion Criteria:\n\n* Patients on anti-platelets\u002Fanti-coagulants\n* Patients with inherited or acquired bleeding disorders\n* Patients with any acute medical condition predisposing to bleeding\n* Hormonal contraceptives\n* Known Allery to TXA\n* Female hormonal replacement therapy","ALL","18 Years","60 Years",{"count":85,"type":86},140,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are:\n\nDoes TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding.\n\nParticipants will:\n\nReceive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery",[92,93,94],"Hemorrhage","Bariatric Surgery","Obesity, Morbid",[96,23,97,98,99],"Bariatric surgery","Hemorrhage in bariatric surgery","RCT","Randomised controlled trial","2025-07-29",{"date":102,"type":103},"2025-08-01","ACTUAL",{"date":105,"type":103},"2023-06-12",{"date":107,"type":86},"2025-08-31",{"name":5,"class":6},1]